Tenderwize
Retour à la recherche

Non-exclusive rebate agreement for Aflibercept injectable solution in vial

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 125 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschl. nicht exkl. Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines OH-Modells zum WS Aflibercept (ATC-Code nach WHO: S01LA05; ausgen. 114,3 mg/ml) als Injektionsl. in einer Durchstechflasche

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The exact submission process is unclear because the structured data says electronic submission is not allowed, while th...

Demand and purchase volume are explicitly unknown, and no minimum quantity is guaranteed.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial.
  • Open-House participation model: any interested pharmaceutical company may join during the participation period if it meets and accepts the participation conditions.
Afficher le résumé complet

This is an Open-House supply arrangement for non-exclusive rebate agreements under §130a(8) SGB V for Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial. The procedure is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no exclusivity. The notice indicates electronic communication via DTVP, but participation documents must be obtained from the project room after access approval. The contract ends no later than 31.12.2026, and the purchase volume is unknown with no minimum quantity guaranteed.

Risques

The exact submission process is unclear because the structured data says electronic submission is not allowed, while th...

Demand and purchase volume are explicitly unknown, and no minimum quantity is guaranteed.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company or its local representative may participate only if it itself qualifies as a pharmaceutical company for the offered product.
  • No Russia-related connection within the meaning of Article 5k of Regulation (EU) No 833/2014, as amended by Regulation (EU) 2022/576, must be declared using the provided...

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for Aflibercept injectable solution in vial

Single lot covering non-exclusive rebate agreements for Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial. This is an Open-House model with no exclusivity, no individual negotiations, and unknown demand/volume. Place of performance is Dresden, Germany, with performance also referenced for Saxony and Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Dec 2025 - Dec 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Dec 31, 2026

Détails de la procédure

Date de publication
11 Nov 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
750728-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30